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Abstract The 223Ra, 224Ra, and 225Ra radioisotopes
exhibit very attractive nuclear properties for applica-
tion in radionuclide therapy. Unfortunately the lack of
appropriate bifunctional ligand for radium is the
reason why these radionuclides have not found
application in receptor-targeted therapy. In the present
work, the potential usefulness of the NaA nanozeolite
as a carrier for radium radionuclides has been studied.
224Ra and 225Ra, a-particle emitting radionuclides,
have been absorbed in the nanometer-sized NaA
zeolite (30–70 nm) through simple ion exchange.
224,225Ra-nanozeolites exhibited very high stability in
solutions containing physiological salt, EDTA, amino
acids, and human serum. To make NaA nanozeolite
particles dispersed in water their surface was modified
with a silane coupling agent containing poly(ethylene
glycol) molecules. This functionalization approach let
us covalently attach a biomolecule to the NaA
nanozeolite surface.
Keywords Radiotherapy  Nanomedicine 
Nanozeolite  Radium radionuclides  Drug
delivery
Introduction
It has been shown that ionizing radiation emitted by
radionuclides is effective in the treatment of various
types of cancers (Boyle and Levin 2008; Zoller et al.
2009). To minimize side effects, radiolabeled agents
should be used that are selectively taken up by cancer
cells, confining the radiation to the tumor, hence
minimizing damage to normal cells (Carlsson et al.
2003; Cutler et al. 2013). For this purpose, tumor-
selective peptides, monoclonal antibodies (mAbs), or
organ-specific proteins are used. Crucial for the
success of this approach are bifunctional ligands
which can be attached to a protein and can bind the
radioactive metal cation rapidly and selectively
(Schubiger et al. 1997; Volkert and Hoffman 1998;
Neves et al. 2005). The vast majority of radionuclides
used in targeted radiotherapy are metals with strong
ability to form stable complexes. These metals can be
attached to a biomolecule through multidentate cyclic
or acyclic ligands. However, there are radionuclides
with very attractive nuclear properties, which can be
used in nuclear medicine, but cannot be stably bound
to biomolecules by bifunctional ligands. To this group
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belong, for example, radionuclides of radium, which
forms very weak complexes.
Radium radioisotopes: 223Ra (t1/2 = 11.43 days),
224Ra (t1/2 = 3.66 days), and
225Ra (t1/2 = 14.8 days)
show very attractive nuclear properties for application
in radionuclide therapy. These radionuclides decay
through a cascade of short-lived a and b- particle
emitters to stable lead and bismuth, releasing a high
total energy of about 28 MeV (Fig. 1). There are four
a particles emitted in each decay series, thus thera-
peutically relevant doses can be delivered from low
amount of injected activity. The relatively long half-
lives give time for preparation, quality control, and
shipment of the radiopharmaceuticals. Radium radio-
nuclides can be obtained from their long-living
parental radionuclides: 223Ra from 227Ac (t1/2 =
21.8 years), 224Ra from 228Th (t1/2 = 1.9 years), and
225Ra from 229Th (t1/2 = 7,880 years).
227Ac can be
produced by neutron irradiation of natural radium,
229Th by extraction from large stocks of 233U, and
228Th as the decay product of 232U.
The lack of appropriate bifunctional ligand is the
reason why radium radionuclides have not found
application in receptor-targeted therapy. As already
mentioned the Ra2? cation, like other cations of group
2, does not form stable complexes, therefore labeling
of biomolecules with 223,224,225Ra is a very difficult
task. Additionally, a chelating agent is required which
could bind radium radionuclide, as well as control the
fate of the daughter radionuclides and withstand the
immense a-particle recoil energy of 100–200 keV,
which is greater than the binding energy in macrocy-
clic metal ion complexes.
Previous studies on binding 223Ra to biomolecules
by its complexation with tetraazacarboxylic acids,
cryptands, and calixarenes were unsuccessful (Hen-
riksen et al. 2002). Also application of liposomes as
carriers for 225Ac, 227Th, and 223 Ra, proposed by
Henriksen and co-workers was not brought into
practice because of the necessity to carry out many
operations with radioactive liposomes (Henriksen
et al. 2004).
Nanotechnology can help to overcome these lim-
itations and bring fundamental changes in creating
new diagnostic and therapeutic radiopharmaceuticals
(Kairem et al. 2008; Ting et al. 2010; Hong et al.
2009). Radionuclides with specific emission proper-
ties can be incorporated into nanoparticles (NPs) and
223Ra
219Rn
215Po
211Pb
211Bi
207Tl
207Pb
α, 11.4 d
5.7 MeV
α, 3.96 s
6.8 MeV
α, 1.78 ms
7.4 MeV
β, 36.1 min
0.447 MeV
α, 2.17 min
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β, 4.77 min
1.42 MeV
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α, 3.66 d
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α, 55.6 s
6.3 MeV
α, 0.15 s
6.8 MeV
β, 10.64 h
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α, 60 min
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β, 3 min
1.79 MeV
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225Ac
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209Pb
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β, 15 d
0.375 MeV
α, 9.9 d
5.9 MeV
α, 4.9 min
6.3 MeV
α, 0.032 s
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5.8 MeV
β, 3.2 h
0.644 MeV
stable
Fig. 1 The decay series of radium radionuclides
Page 2 of 11 J Nanopart Res (2013) 15:2082
123
used for radionuclide therapy and radio-imaging. NPs
are particularly suitable for the delivery of a or b-
emitters in radioimmunotherapy. The advantage of
NPs is the potential for containing several radioactive
atoms within a single carrier. This feature is useful
when a target tissue has only a few receptors per cell,
which limits the dose that can be delivered (McDevitt
et al. 1998).
NPs can deliver radionuclides using either passive
or active targeting strategy. The passive targeting
accumulation of NPs takes place in non-specific way
through enlarged gap junctions in tumor endothelial
cells (Carmaliet and Jain 2000). This type of targeting,
which enables macromolecules to selectively accu-
mulate in the tumor tissue, is called enhanced perme-
ation and retention (EPR). Unfortunately, local drug
deposition is unfeasible for larger tumors with poor
vascularization. Target specificity is then achieved
through hybrid NPs produced by conjugating NPs with
tumor-specific biomolecules, including mAbs, apta-
mers, peptides, or various receptor-specific substrates
(Hamoudeh et al. 2008; Chanda et al. 2010).
The recently investigated nanosystems include,
among others, liposomes, silica and silicon NPs (Patel
et al. 2010), quantum dots (Patt et al. 2010), noble
metals NPs (Chanda et al. 2010; Kucka et al. 2006),
dendrimers (Longmire et al. 2008), lanthanum phos-
phate NPs (Woodward et al. 2011), and polymer-based
NPs (Cho et al. 2007). The possibility of combining
imaging and therapeutic modalities in a single NP
makes them very attractive in personalized medicine
(theranostic approach) (Luk et al. 2012).
In the present work, we propose to use nanozeolite
whose channels and cavities will be filled with cations
of 223Ra, 224Ra, and 225Ra by means of simple ion
exchange, without any additional operations.
Zeolites are biocompatible crystalline aluminosil-
icates composed of tetrahedral structures which build
open framework consisting of channels and cages of
molecular dimensions. Each tetrahedron containing
aluminum formally bears one unit of negative charge,
because aluminum atom is connected to four oxygen
atoms. To make the crystal electrically neutral metal
cations (e.g., Na?, K?, Ca2?) are present in the
interstices of the zeolitic framework. We can distin-
guish many different kinds of zeolite structures with
different selectivity and ion-exchange properties
(Sherry 1969). The use of nanozeolite with suitable
structure should enable stable encapsulation of radium
radionuclides inside the framework. In the light of the
Eisenman–Sherry theory of cation-exchange selectiv-
ity, zeolites exhibit greater or smaller preference for
one cation over another (Reichenberg 1966). Taking
into account these rules, we can predict that zeolites
with high aluminum content, like the A-type nanoze-
olite, will prefer Ra2? than Na?, K?, Mg2?, and Ca2?,
i.e., cations with high concentrations in physiological
liquids.
Till now, only one paper was devoted to the
application of radiolabeled nanozeolite in nuclear
medicine. Tsotsalas et al. used nanozeolite L to fill it
with c-emitter 111In3?, through simple ion exchange
(Tsotsalas et al. 2010). The zeolite L has relatively
large windows (r = 0.35 nm), in comparison with
In3? ionic radius (ri = 0.080 nm, CN = 6), which
results in leakage of 111In under physiological condi-
tions. To avoid the leakage, the entrances to the
channels were closed by specifically designed silanol
stopcocks. The authors concluded that the obtained
samples were highly stable in physiological liquids
and may enable a large variety of functionalities on the
external surface of nanozeolite L. However, the
proposed procedure requires difficult post-labeling
operations.
The aim of our work was to synthesize the NaA
nanozeolite of small dimension (\100 nm), to load
it with radium radionuclides, and to study stability
of the labeled nanozeolite in various biological
liquids.
Experimental
Materials
The following chemical reagents were used: Ludox
CL-X colloidal silica 45 % suspension in water
(Sigma-Aldrich, USA), sodium aluminate (Sigma-
Aldrich, Germany), sodium hydroxide (pure p.a.,
Chempur), 2(methoxy(polyethylenoxy)propyltri-
methoxysilane (silane-PEG, abcr GmbH & Co. KG,
Germany), ethanol (99,9 %, POCH, Poland), sodium
chloride (POCH, Poland), EDTA (POCH, Poland), L-
cysteine (Sigma-Aldrich, Japan), tetramethylammo-
nium hydroxide (TMAOH 25 % wt., Sigma-Aldrich,
Switzerland), nitric acid (POCH, Poland), hydrochlo-
ride acid (POCH, Poland), human serum (obtained
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from a donor and stored at -20 C), and distilled
water (Millipore).
Radionuclides
224Ra was produced from a generator based on the
232U/228Th pair (Narbutt and Bilewicz 1998). About
5 MBq of 232U was adsorbed in a small column on
Teflon grains impregnated with HDEHP. Next, 224Ra
was eluted with 0.1 M HNO3, the eluate from the
generator evaporated to dryness and the remaining
residue containing radioactivity was re-dissolved in
200 ll of 0.1 M HCl.
225Ra was obtained from the 229Th source available
at the Institute for Transuranium Elements, Karlsruhe,
Germany. The source contains 214.5 mg of 229Th
(t1/2 = 7,340 years), which makes possible to isolate
1.60 GBq of 225Ra every 9 weeks. In order to isolate
225Ra in the first step 225Ra and 225Ac were separated
from 229Th using ion exchange (Apostolidis et al.
2005), followed by separation of 225Ra from 225Ac
using extraction chromatography (Zielinska et al.
2007). Briefly, thorium batch, consisting of 500 ml of
Dowex 1 9 8, anion-exchange resin, was washed 5–6
times using each time 100 ml of 8 M HNO3. The
combined washing solutions, containing 225Ra, 225Ac,
and 3–5 % of 229Th/232Th, were evaporated to almost
dryness, put into 20 ml of 8 M HNO3 and filtered
through a preliminary column (1.0 ml volume) to
remove organic impurities. Next, the filtrate was
loaded into an anion-exchange column (Dowex 1 9 8,
100–200 mesh, column volume 80 ml). 225Ra and
225Ac were eluted by washing with 250–300 ml of
8 M HNO3, and the eluate was evaporated to nearly
dryness and put into 10 ml of 4 M HNO3 for
subsequent radium/actinium separation by extraction
chromatography. Subsequently, the 225Ra/225Ac prod-
uct from the anion-exchange separation in 4 M HNO3
was loaded into a UTEVA/RE-resin column cascade
(volume of each equal to 1.6 ml). Under these
conditions, residual thorium was extracted on the
UTEVA column. Next, 225Ra was washed out from the
column with no more than 20 ml of 4 M HNO3 and
evaporated to reduce its volume. Before each exper-
iment, 225Ra was purified from its decay products
(225Ac, 213Bi) on a chelating resin. For this aim 1 ml of
the solution containing 225Ra with its decay products
was adsorbed on a small column (d = 3 mm,
h = 20 mm) filled with cation-exchange resin
Chelex-100. Next, 225Ra was quantitatively eluted
with 0.001 M HCl solution.
Instrumentations
The particle size and morphology of the NaA
nanozeolite were determined by scanning electron
microscopy (SEM, Zeiss) and transmission electron
microscopy (TEM, LEO 912AB). Identification and
determination of crystallinity of the nanozeolite were
carried out by X-ray diffraction (XRD, D8 Advance)
using Vantec detector with Cu Ka radiation (1.54 A˚)
operated at voltage 40 kV and current 20 mA. The
average size and zeta potential (f) were measured by
dynamic light scattering (DLS, Malvern, UK). Ther-
mal stability of modified and unmodified samples was
determined by thermogravimetric analysis (TGA,
Q500, TA Instruments, US).
Gamma-spectrometry was carried out using a
calibrated intrinsic Ge detector (crystal active volume
100 cm3) and PC-based Multichannel Analyzer
(MCA, Canberra). The detector had a resolution of
0.8 at 5.9 keV, 1.0 at 123 keV, and 1.9 at 1,332 keV.
Radioactivity of 224Ra and 212Pb was quantified by
their 237.75 keV c-ray, and by the 725.29 keV c-ray
from 212Bi. Radioactivity of 225Ra was quantified
by its 40 keV c-ray, by the 99.8 keV c-ray from 225Ac,
by the 217.86 keV c-ray from 221Fr, and by the
439.8 keV c-ray from 213Bi. The type of the decay
product was confirmed by calculation of T1/2 from the
decay curves.
Synthesis of NaA nanozeolite
Nanocrystalline NaA zeolite was prepared according
to modified procedures described in the papers (Wang
et al. 2002; Hu et al. 2009). The aluminosilicate gel
composition was
NaOH
SiO2
¼ 2:21; TMAOH
SiO2
¼ 2:21; SiO2
Al2O3
¼ 3:0;
H2O
SiO2
¼ 85:79
The synthesis procedure was divided into two steps.
In the first step, sodium aluminate was added to
aqueous sodium hydroxide solution and kept under
stirring to complete dissolution. Then the required
amount of tetramethylammonium hydroxide (tem-
plate) was slowly added and the solution stirred
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continuously for 24 h at room temperature. The
second step was the hydrothermal treating. The silica
gel was added dropwise to the solution under stirring
and the mixture was immediately placed in an oil bath
equipped with magnetic stirrer and temperature con-
troller. Hydrothermal crystallization was carried out
for 48 h, at 100 C with rotation rate 750 rpm. The
obtained nanocrystals were cooled to room tempera-
ture and washed with distilled water by centrifugation
at 13,500 rpm (2-16P Spincontrol Universal, Ger-
many) until pH\8. Next, the sample was calcinated at
500 C for 3 h to remove the template.
Synthesis of silane-PEG modified NaA
nanozoelite
Modified NaA nanozeolite has been synthesized
according to the procedure described in the book
(Hermanson 2008). The 50 ml of solution containing
4 % water in ethanol (v/v) was prepared and its pH
was adjusted to 4.5–5.5 with acetic acid. 2 ml of
silane-PEG solution was added dropwise to the acidic
water/ethanol solution under stirring at room temper-
ature. The reagents were stirred continuously for
5 min. After that, 50 mg of nanozeolite NaA was
added to the solution and stirring was continued for
1 h, at room temperature. The obtained product was
washed several times with ethanol to remove excess
silane-PEG compound and dried at 110 C for 30 min.
Labeling NaA nanozeolite with 224Ra and 225Ra.
Stability studies of 224/225Ra-nanozeolites and
224/225Ra–nanozeolites-silane-PEG
224Ra and 225Ra nanozeolites were prepared by
exchanging Na? for 224,225Ra2?. To this end,
100 mg of nanozeolite sample was introduced into
the eppendorf tube, suspended in 2 ml of the 224RaCl2
solution [A & 0.5 MBq], and sonificated in ultra-
sound bath for 15 min. The eppendorf tube was gently
shaken on circular stirrer for 2 h. After that time, the
suspension was centrifuged for 10 min at 10,000 rpm
(MiniSpin, Eppendorf, Poland). The supernatant was
separated from the precipitate and its activity was
measured. Afterward, the sample was washed several
times with deionized water, then suspended in 1 ml of
water and sonificated (Polsonic, Poland). In order to
study stability, 100 ll of the 224Ra-nanozeolite sus-
pension was incubated in several solutions: saline,
PBS buffer, EDTA, L-cysteine, and human serum (at
37 C) by shaking for 2 h. Then, the suspensions were
centrifuged under the same conditions as aforemen-
tioned and activities of the supernatants were mea-
sured. Afterward, the precipitates were re-suspended
in the supernatants and stability studies were extended
to 24 h. The same procedure was used for 225RaCl2
(A & 100 kBq). The stability studies for 225Ra were
carried out for 4 days. Stability studies of NaA
nanozeolites modified with PEG and radiolabeled
either with 224Ra or 225Ra were carried out in exact
conditions as described above.
The blank tests with the serum and radionuclide
solution, but without nanozeolites were carried out to
estimate the percentage of possible binding of free
radionuclides (224,225Ra2?, 212Pb2?, 208Tl?,
212,213Bi3?, 225Ac3?, 221Fr?) to proteins present in
the serum. After certain time of incubation of blank
sample, 1 ml of human serum, combined with 5 ll of
224,225RaCl2 solution, was centrifuged with the same
speed as that used with nanozeolites samples
(10,000 rpm) and the activity of the serum taken from
the top of centrifuged sample was measured on
gamma-spectrometer.
Results and discussion
The NaA nanozeolite was successfully prepared by
hydrothermal synthesis. Figure 2 shows XRD patterns
of the obtained sample. The NaA nanozeolite structure
was identified by comparing relative intensities in its
XRD powder pattern (Fig. 2a) with those reported in
Fig. 2 XRD pattern of (a) NaA nanozeolite and (b) A zeolite
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the literature (Fig. 2b) (Gramlich and Meier 1971).
The two powder diffraction patterns were found to be
in good agreement. The broadened XRD pattern peaks
observed in the obtained sample are indicative of small
size of the crystalline product.
Crystallinity of the NaA nanozeolite was calculated
using Eq. (1) (Cullity 1956):
%Cð Þ ¼ 100  Ihkl
Ib þ Ihkl ð1Þ
where Ihkl is the connected integral XRD peak
intensity and Ib is the integral background intensity
for the same plane. The obtained nanozoelite was
found to exhibit about 90.9 % of crystallinity.
Scherrer’s formula (Eq. 2) was used to calculate the
crystallite dimension (Cullity 1956):
t ¼ 0:9 k
BcoshB
ð2Þ
where B is the diffraction curve width measured at an
intensity equal to half the maximum intensity in
radius, k is the X-ray wavelength, and hB is the Bragg
angle. The average crystallite size of the NaA
nanozeolite is about 43 nm. Both calculations were
made with reference to the most significant peak
(200).
Size distribution and shape of NaA nanozeolite
particles were investigated by DLS (Fig. 3), SEM and
TEM (Fig. 4).
It can be seen from the SEM images that the
particles with shape similar to parallelepiped, with the
size between 50 and 170 nm, were formed. The
particles seem to have tendency to aggregate into the
size from 200 nm to even 1 lm. However, the DLS
analysis shows that the suspended in water NPs are of
the size between 40 and 120 nm, which is in good
agreement with the SEM results. Disintegration of the
agglomerates has been obtained by sonification in an
ultrasound bath for 15 min, followed by filtration on
syringe filters with 0.22 lm pores (Millipore). To
verify the size range of the NPs purified by sonification
and filtration the TEM image was made (Fig. 4b). The
Fig. 3 DLS analysis of
NaA nanozeolite
Fig. 4 a SEM and b TEM images of NaA nanozeolite
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TEM image shows that the filtration process is crucial
for separating the small NPs from agglomerates and
for getting a well-dispersed sample.
The obtained sample of the NaA nanozeolite was
used for absorption of 224,225Ra radionuclides by ion
exchange with Na? ions, which are present in the
channels and interstices of NPs. The percentage of
absorption for both radionuclides was above 99.9 %.
The studied nanozeolites exhibited high affinity for
both radium isotopes, with the distribution coefficient
exceeding 104 cm3 g-1. The distribution coefficient
was calculated as the ratio of the equilibrium activity
in 1 g of the solid phase to that in 1 ml of the aqueous
phase. Stability of radiolabeled nanozeolites was
studied in various solutions containing: physiological
salt, complexing agent (EDTA), buffer (PBS), amino
acid (L-cysteine), and human serum. In all studied
solutions, the leakage of 224,225Ra from the nanozeo-
lites was below 0.5 %. In solution only the decay
products of radium radionuclides were found. Results
of the stability study are shown in Table 1.
Table 1 shows the percentage of liberated activity
from each daughter radionuclide, determined by its
decay characteristic c-ray peak. The percentage values
of each radionuclide refer to the absolute amount of
radionuclide in the sample. The NaA nanozeolite
labeled with 224Ra is very stable in the physiological
salt and in PBS buffer solutions. The activities of the
samples were near background. The examined sample
is less stable in solutions containing either complexing
agent (EDTA) or amino acid (L-cysteine). The c-
radioactivity, which was found in the solutions, has
been attributed to 212Pb, 208Tl, 212Bi (the decay
products of 224Ra). When the decay series is taken
into consideration, we can assume that due to radio-
active equilibrium certain amounts of 208Tl and 212Bi
originate from 212Pb decay. But there are also small
amounts of these radionuclides, which were elimi-
nated from nanozeolitic structure, due to leaching by
aqueous solution. Confirmation of high stability of
224Ra-nanozeolite was made after human serum study,
which showed that the percentage of released radio-
nuclides was low. The extension of the incubation
time to 24 h has brought no changes in the percentage
of liberated radioactivity.
225Ra has been purified from its decay products
before labeling. The purification made possible to
obtain NPs labeled only with radium cations, which
are strongly bound inside nanozeolite structure.
Therefore, there has been no leakage of radioactivity
to the solution in 2 days. After that time, the first c-
radioactivity, due to the presence of 225Ac, 221Fr, and
213Bi (the daughter radionuclides of 225Ra), has been
found. For this reason, stability studies have been
Table 1 Stability study of the NaA nanozeolite labeled with 224,225Ra
Solution % of liberated radioactivity
224Ra (1 day of incubation) 225Ra (2 h of incubation) 225Ra (4 days of incubation)
0.9 % NaCl 0.1 ± 0.1 (212Pb) – 1.1 ± 0.5 (221Fr)
0.7 ± 0.5 (208Tl) 3.0 ± 1.2 (213Bi)
1.0 ± 0.3 (212Bi)
0.02 M PBS 0.4 ± 0.1 (212Pb) – 0.9 ± 0.7 (221Fr)
0.6 ± 0.2 (208Tl) 1.8 ± 0.8 (213Bi)
0.6 ± 0.9 (212Bi)
10-3 M EDTA 4.8 ± 2.3 (212Pb) 0.5 ± 0.02 (221Fr, 213Bi) 5.5 ± 2.5 (225Ac)
7.8 ± 0.8 (208Tl) 5.2 ± 1.4 (221Fr)
9.4 ± 0.6 (212Bi) 10 ± 0.8 (213Bi)
10-3 M cysteine 5.3 ± 3.7 (212Pb) 0.4 ± 0.1 (221Fr, 213Bi) 1.2 ± 0.5 (225Ac)
7.9 ± 5.5 (208Tl) 0.8 ± 0.4 (221Fr)
7.5 ± 5.5 (212Bi) 13 ± 2.3 (213Bi)
Human blood serum 2.6 ± 1.5 (212Pb) – 2.3 ± 1.9 (225Ac)
7.2 ± 0.9 (208Tl) 2.7 ± 0.2 (221Fr)
6.2 ± 0.5 (212Bi) 7.4 ± 0.8 (213Bi)
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enlarged to 4 days. The nanozeolite NaA exhibits also
high affinity for the Fr? cation (the biggest alkali metal
cations), which results in low leaching of 221Fr in the
solution. The results were similar to those with 224Ra,
what means that the assessed values of radionuclide
amounts liberated from nanozeolite indicate that there
is no leakage of 225Ac in physiological salt and in PBS
buffer, and the leakage of 221Fr and 213Bi are
negligible. It points out to high stability of radiola-
beled NaA nanozeolites in these solutions. Labeled
zeolite NPs are unstable in EDTA and cysteine
solutions. It should be noted that in EDTA solution
whole amount of 221Fr originates from 225Ac decay,
whereas the percentage of 213Bi released is twice as
big, which shows that this radionuclide was also
released from nanozeolites crystals. The same behav-
ior was also observed in cysteine solution. Insignifi-
cant amount of radioactivity has been released after
incubation in human serum at 37 C, which points out
to high stability of 225Ra-nanozeolites. The described
blank tests with human serum and free radionuclides
have shown that 224,225Ra, 225Ac, and 221Fr radionuc-
lides do not react with proteins present in the serum
and that significant amount of 208Tl and small amounts
Scheme 1 Functionalization of the NaA nanozeolite surface with silane coupling agent (silane-PEG)
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of 212,213Bi binds to proteins. Thus, the presented
percentage values of stability studies with human
serum were re-calculated and adequately increased.
In the experiments described above unmodified
nanozeolites have been used. In order to make the
surface of the NaA nanozeolite crystals more hydro-
philic and biocompatible, a batch of the nanomaterials
has been modified by covalent attachment of PEG
molecules. The modification of the NaA nanozeolite
surface was fast and simple (Scheme 1). The func-
tionalization of the surface was made by using silane
coupling agent with three methoxy groups and PEG
molecules. Silane-PEG agent was attached to the
surface of NPs by the siloxane bonds formation. The
TGA was used to confirm the modification (Fig. 5).
It can be seen on both thermograms that there is a
loss of mass (*5 ± 1.5 %) in the range from 80 to
100 C, which can be attributed to desorption of
physically adsorbed water molecules. The consecutive
loss of mass is observed between 100 and 800 C
(*8 ± 2 %), what is associated with desorption of
water occluded in the interstices and channels of
nanozeolite. Additionally, on the modified nanozeo-
lite’s thermogram a loss of mass at about 390 C
(*3 ± 1.5 %) is observed, which can be attributed to
degradation of the silane-PEG molecules.
The zeta potential (n) was measured in order to give
an additional confirmation of the successful modifi-
cation of NaA nanozeolite surface. We found that the
zeta potential has changed from -32.5 ± 1.7 mV for
unmodified NPs to -13.4 ± 1.9 mV for modified
ones. The zeta potential was measured in phosphate
buffer (pH 7.4).
The labeling with 224,225Ra and stability studies
were also carried out for PEGylated nanozeolite
(Table 2). No significant differences were observed
between results obtained for functionalized NPs and
for those without modification. This indicates that the
access to pores and channels of NaA nanozeolite has
not been blocked by covering the surface with PEG
molecules.
Conclusions
Our preliminary results have shown that the NaA
nanozeolite can be used as a carrier for 224Ra and
225Ra and for all of their daughter radionuclides. We
have also shown that PEG molecules can be covalently
attached to the NaA nanozeolite surface using the
silanization approach. The modification of the surface
makes the NPs stable and dispersed in water, which
was confirmed by zeta potential measurement. Addi-
tionally, it is worth to notice that 225Ra radionuclide is
a soft b- emitter, whereas the alpha emission origi-
nates from its decay products. Therefore, by formation
of radiopharmaceuticals labeled with 225Ra, previ-
ously separated from all of daughter radionuclides, we
can obtain radiobioconjugate with very low b-
activity. The significant emission of a-particle occurs
from 225Ac and its decay products after few days after
injection. Thus, 225Ra can be used to label
Fig. 5 TGA thermograms of a unmodified and b modified NaA nanozeolite
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macromolecules (for example mAbs) with slow phar-
macokinetics and biodistribution time. For example,
IgG molecules often reach maximum of accumulation
after few days (Henriksen et al. 2004).
In future experiments we intend to use the same
procedure of modification, in order to cover the
surface with silane coupling agent containing
N-hydroxysuccinimide ester and afterward attach
targeting vectors like octreotide, substance P or mAbs.
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